NCT04595175 (CONSERVE-HCW) is a clinical trial in COVID-19 Infection, sponsored by Brian Tiffany, MD.

Who is sponsoring NCT04595175?

NCT04595175 is sponsored by Brian Tiffany, MD.

What condition does NCT04595175 study?

NCT04595175 studies COVID-19 Infection.

Is NCT04595175 still recruiting?

NCT04595175 is currently status unknown. Last updated 20 October 2020.

Last reviewed 2020-10-20 · How we verify

NCT04595175: CONSERVE-HCW

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW)

Status unknown Last updated 20 October 2020

What this trial tests

trial in COVID-19 Infection in 2,000 participants. Status unknown.

Timeline

10 June 2020

Primary endpoint
30 June 2021

30 December 2021

Quick facts

Lead sponsor	Brian Tiffany, MD
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	10 June 2020
Primary completion	30 June 2021
Estimated completion	30 December 2021
Sites	1 location across United States

Conditions studied

COVID-19 Infection — all drugs for COVID-19 Infection →

Sponsor

Brian Tiffany, MD

Who can join

18 and older, any sex, with COVID-19 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Investigators propose a multi-center, observational, longitudinal, cohort study of the serology and wellness of HCWs over a year of the COVID-19 pandemic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COVID-19 Infection

Currently open trials in the same condition.

NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04595175 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brian Tiffany, MD
Last refreshed: 20 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04595175.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing